Individual subsets of thyroid cancer are beginning to be discovered as indolent disease, Randolph explains. These include microcarcinomas, NIFTP lesions, and smaller tumors without nodal disease. These clinical parameters will be made more robust via a better understanding of the genomic makeup of these lesions.

Less aggressive treatment can then be given to patients who have a disease that is biologically understood to be a more indolent course, Randolph adds.

Individual subsets of thyroid cancer are beginning to be discovered as indolent disease, Randolph explains. These include microcarcinomas, NIFTP lesions, and smaller tumors without nodal disease. These clinical parameters will be made more robust via a better understanding of the genomic makeup of these lesions.

Less aggressive treatment can then be given to patients who have a disease that is biologically understood to be a more indolent course, Randolph adds.